Monday, 30 April 2018

Discontinuing epidermal growth factor receptor-tyrosine kinase inhibitor during second-line chemotherapy: is the evidence strong enough? full article pdf download

Title of article - Discontinuing epidermal growth factor receptor-tyrosine kinase inhibitor during second-line chemotherapy: is the evidence strong enough?

Abstract

Late presentation of aortic false aneurysm following repair of acute type A aortic dissection occurs in 10% to 24% of cases. This condition is associated with high mortality if left untreated. Herein we describe a combination of surgical strategies that we believe may be used effectively to reduce the surgical risk of these complex operations.

CLICK HERE for Full article


Click button above to go to original article link with complete article details for Discontinuing epidermal growth factor receptor-tyrosine kinase inhibitor during second-line chemotherapy: is the evidence strong enough?

Please CLICK HERE to discuss with us on facebook about this article.

Click below for Details of research Institute


Details of Journal for Discontinuing epidermal growth factor receptor-tyrosine kinase inhibitor during second-line chemotherapy: is the evidence strong enough?

Journal Title - Annals of translational medicine

ISSN - 2305-5839

Volume - 3

Issue - 14

Publish date - 2015-Aug

Language - eng

Country - China

No comments:

Post a Comment